Evidence map›Paper›PMID 35514261›Full record

ArticlePlatelets2022

Evidence for a PI3-kinase independent pathway in the regulation of Rap1b activation downstream of the P2Y12 receptor in platelets.

Carol Dangelmaier, Satya P Kunapuli

Open access · greenAbstract read
In one paragraph

Article in Platelets, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Association ofRevista de neurologia · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Carol DangelmaierSol Sherry Thrombosis Research Center and the Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Satya P KunapuliSol Sherry Thrombosis Research Center and the Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Temple University · US

Funding

Novel signaling molecules regulating platelet activationR35HL155694 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI Satya P. Kunapuli · 2021 to 2026
$5.6M
Functional PKC Isoforms in PlateletsR01HL093231 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI KUNAPULI, SATYA P. · 2009 to 2017
$3.6M
Novel small G protein pathway regulators of GPVI signaling in plateletsR01HL137207 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI GOLDFINGER, LAWRENCE E, KUNAPULI, SATYA P. · 2017 to 2020
$2.5M
Novel regulation of CLEC-2 signaling in PlateletsR01HL132171 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI KUNAPULI, SATYA P. · 2017 to 2020
$1.8M
Novel functional protein tyrosine phosphatases in plateletsR01HL137721 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI KUNAPULI, SATYA P. · 2018 to 2020
$1.6M
NHLBI NIH HHS R01 HL093231NHLBI NIH HHS R01 HL132171NHLBI NIH HHS R01 HL137207NHLBI NIH HHS R01 HL137721NHLBI NIH HHS R35 HL155694
6 · The paper itself

Abstract

Platelet activation by adenosine diphosphate (ADP) is mediated through two G-protein-coupled receptors, P2Y1 and P2Y12, which signal through Gq and Gi, respectively. P2Y1 stimulation leads to phospholipase C activation and an increase in cytosolic calcium necessary for CalDAG-GEF1 activation. Engagement of P2Y12 inhibits adenylate cyclase, which reduces cAMP, and activation of PI3-kinase, which inhibits RASA3 resulting in sustained activated Rap1b. In this study we activated human platelets with 2-MeSADP in the presence of LY294002, a PI3-kinase inhibitor, AR-C69931MX, a P2Y12 antagonist or MRS2179, a P2Y1 antagonist. We measured the phosphorylation of Akt on Ser473 as an indicator of PI3-kinase activity. As previously shown, LY294002 and ARC69931MX abolished 2MeSADP-induced Akt phosphorylation. MRS2179 reduced ADP-induced Akt phosphorylation but did not abolish it. Rap1b activation, however, was only reduced, but not ablated, using LY294002 and was completely inhibited by ARC69931MX or MRS2179. Furthermore, 2MeSADP-induced Rap1b activation was abolished in either P2Y1 or P2Y12 null platelets. These data suggest that ADP-induced Rap1b activation requires both P2Y1 and P2Y12. In addition, although stimulation of P2Y12 results in PI3-kinase activation leading to Akt phosphorylation and Rap1b activation, Rap1b activation can occur independently of PI3-kinase downstream of P2Y12. Thus, we propose that the P2Y12 receptor can regulate Rap1b, possibly through RASA3, in a pathway independent of PI3-kinase.

Indexed as

Phosphatidylinositol 3-KinasesReceptors, Purinergic P2Adenosine DiphosphateAdenylyl CyclasesBlood PlateletsCalciumHumansProto-Oncogene Proteins c-aktPurinergic P2Y Receptor Antagonistsrap GTP-Binding ProteinsReceptors, Purinergic P2Y1Receptors, Purinergic P2Y12ThionucleotidesType C PhospholipasesAdenosine DiphosphateAdenylyl CyclasesCalciummethylthio-ADPPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPurinergic P2Y Receptor AntagonistsRAP1B protein, humanrap GTP-Binding ProteinsReceptors, Purinergic P2Receptors, Purinergic P2Y1Receptors, Purinergic P2Y12ThionucleotidesType C PhospholipasesPI3KRap1BRASA3

Identifiers

PMID35514261
PMCPMC9547944
OpenAlexW4229056509

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.